# RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration

> **NCT03633084** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ribomic USA Inc** · enrollment: 9 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** RBM-007 Injectable Solution

## Key facts

- **NCT ID:** NCT03633084
- **Lead sponsor:** Ribomic USA Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-29
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03633084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03633084, "RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03633084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*